<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[《中国临床新医学》杂志编辑部 -->Special Topic on Female Fertility Preservation]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in laboratory techniques for fertility preservation]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20260304&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　With the advancement of treatment techniques for malignant tumors and a significant increase in survival rate of young cancer patients, as well as the delay in childbearing age due to social factors, fertility preservation(FP) has become a crucial component in the field of reproductive medicine. This paper aims to systematically sort out the current development status and future trends of FP from the perspective of core laboratory techniques. It focuses on analyzing the principles, standardized procedures, and efficacy evaluation systems of gametes(sperms and oocytes) and embryo cryopreservation using vitrification as the gold standard, and delves into the challenges and post-thaw strategies associated with the cryopreservation of gonadal tissues, such as ovarian tissues and testicular tissues, and makes comments on the potential and bottlenecks of cutting-edge laboratory strategies, including in vitro maturation(IVM) of immature oocytes, in vitro follicle culture(IVFC), and stem cell-based in vitro gametogenesis(IVG). Finally, this paper provides an outlook on the development of FP techniques towards automation, intelligence, and individualized precision.]]></description>
<pubDate>2026/3/31 9:16:41</pubDate>
<category><![CDATA[Special Topic on Female Fertility Preservation]]></category>
<author><![CDATA[ZHOU Zihao, ZHOU Zhongyue, MA Zhuanghong, HOU Sumei, YANG Fan, WANG Sheng, ZHANG Xu, ZHU Yuanchang, DENG Weifen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Zihao, ZHOU Zhongyue, MA Zhuanghong, HOU Sumei, YANG Fan, WANG Sheng, ZHANG Xu, ZHU Yuanchang, DENG Weifen</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20260304&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in the clinical application of ovarian tissue cryopreservation and transplantation in leukemia patients]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20260305&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　The effectiveness and safety of ovarian tissue cryopreservation and transplantation(OTCT)  have been widely verified and have become a routine clinical technique. For the leukemia patients scheduled for haematopoietic stem cell transplantation(HSCT), their preconditioning regimens before HSCT can lead to severe and irreversible damage to the ovarian function, thereby affecting their reproductive potential and ovarian endocrine function. Therefore, OTCT in these leukemia patients has significant clinical significance. However, the potential risk of reintroducing leukemia cells in the patients through the transplanted ovarian cortical fragments remains a key safety concern limiting the widespread application of the technique in these leukemia patients. This paper systematically reviews the application of ovarian tissue cryopreservation(OTC) in leukemia patients, assesses the risk of reintroducing leukemia cells in the patients through the transplanted ovarian cortical fragments, and evaluates the transplantation outcomes of cryopreserved ovarian tissues in the leukemia survivors, with the aim of providing reference for clinical decision-making and practice.]]></description>
<pubDate>2026/3/31 9:16:41</pubDate>
<category><![CDATA[Special Topic on Female Fertility Preservation]]></category>
<author><![CDATA[CHENG Jiaojiao, RUAN Xiangyan, DU Juan, GU Muqing, JIN Fengyu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHENG Jiaojiao, RUAN Xiangyan, DU Juan, GU Muqing, JIN Fengyu</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20260305&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparison of the outcomes of IVF/ICSI cycles and tumor recurrence between SBOT and MBOT patients after fertility-sparing surgery]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20260306&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］　Objective</b>　To compare the ovarian response to controlled ovarian stimulation, embryological and pregnant outcomes between serous borderline ovarian tumor(SBOT) patients and mucinous borderline ovarian tumor(MBOT) patients who underwent fertility-sparing surgery(FSS) followed by in vitro fertilization(IVF), and to evaluate the safety regarding tumor recurrence. <b>Methods</b>　A retrospective analysis was conducted on the clinical data of 63 patients with borderline ovarian tumor(BOT) who underwent in vitro fertilization(IVF)/intracytoplasmic sperm injection(ICSI) in Center for Reproductive Medicine, the Sixth Affiliated Hospital, Sun Yat-sen University from May 2010 to May 2023 after FSS. According to the pathological types after the surgery, the patients were divided into SBOT group(44 cases) and MBOT group(19 cases). The ovarian stimulation parameters, embryological indicators transplantation cycles and pregnant outcomes were compared between the two groups. Firth-corrected multivariable logistic regression was used to analyze the factors associated with tumor recurrence. <b>Results</b>　There were no statistically significant differences between the two groups in terms of baseline characteristics, ovulation induction protocol, fertilization method, days using gonadotropin(Gn), the total dosage of Gn, the number of oocytes retrieved, the number of two-pronuclear(2PN) fertilized oocytes, the number of transferable embryos, the number of high-quality embryos, the rate of 2PN ferlilization per egg, the rate of transferable embryos per egg and the rate of high-quality embryos per egg(<i>P</i>>0.05). The proportion of fresh cycle embryo transfer in the MBOT group was significantly lower than that in the SBOT group(<i>P</i><0.05). There were no significant differences between the two groups in the non-transplantable embryo cycle rate, number of transplanted embryos, number of transplantation cycles, live birth rate per transfer cycle and live birth rate per initiated cycle(<i>P</i>>0.05). Seven patients were lost to follow-up. The recurrence rate was 10.53%(4/38) in the SBOT group and 5.56%(1/18) in the MBOT group, and the difference was not statistically significant between the two groups(<i>χ<sup>2</sup></i>=0.012, <i>P</i>=0.911). Firth-corrected multivariable logistic regression analysis suggested that pathological type was not an independent influencing factor for tumor recurrence. <b>Conclusion</b>　The ovarian response to controlled ovarian stimulation, embryological manifestations and pregnant outcomes followed by IVF/ICSI in SBOT and MBOT patients who underwent fertility-sparing surgery were comparable. There is no significant difference in the recurrence risk between the two different pathological types of BOT.]]></description>
<pubDate>2026/3/31 0:00:00</pubDate>
<category><![CDATA[Special Topic on Female Fertility Preservation]]></category>
<author><![CDATA[LI Yujie<sup>1</sup>, WU Jialin<sup>1</sup>, SUN Wenchao<sup>2</sup>, LI Jingjie<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Yujie<sup>1</sup>, WU Jialin<sup>1</sup>, SUN Wenchao<sup>2</sup>, LI Jingjie<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20260306&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Fertility preservation in an adolescent patient with very severe aplastic anaemia and literature review]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20260307&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］　Objective</b>　To review the diagnosis and treatment process of an adolescent patient with very severe aplastic anaemia(VSAA), and to explore the effectiveness of fertility preservation for adolescent females through ovarian tissue cryopreservation(OTC) combined with in vitro maturation(IVM) of immature oocytes technique. <b>Methods</b>　An adolescent VSAA patient was admitted to the People′s Hospital of Guangxi Zhuang Autonomous Region and was scheduled for hematopoietic stem cell transplantation(HSCT) in July 2025. Before HSCT, the patient underwent fertility preservation through OTC combined with IVM technique, and her diagnosis and treatment data were collected. By searching domestic and overseas literature reports on fertility preservation, the diagnosis and fertility preservation of the patient were analyzed. <b>Results</b>　After ovarian tissue extraction, a total of 3 cumulus-oocyte complexes(COCs) and 10 pieces of ovarian cortex tissues of the patient were obtained through puncture in vitro and aspiration. After IVM for 48 h, a total of 2 oocytes at the metaphase Ⅱ(MⅡ) stage in COCs were freezed by using vitrification. <b>Conclusion</b>　For the adolescent female patients in urgent need of HSCT for treating VSAA, OTC in combination with IVM technique may preserve their fertility to the greatest extent in the short term.]]></description>
<pubDate>2026/3/31 9:16:41</pubDate>
<category><![CDATA[Special Topic on Female Fertility Preservation]]></category>
<author><![CDATA[TANG Huihe<sup>1</sup>, DAI Yan<sup>1</sup>, LI Xinye<sup>1</sup>, MA Hongyan<sup>1</sup>, HUANG Jinxian<sup>1</sup>, CHEN Chaohui<sup>1</sup>, LIU Liling<sup>2</sup>, CHENG Junping<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TANG Huihe<sup>1</sup>, DAI Yan<sup>1</sup>, LI Xinye<sup>1</sup>, MA Hongyan<sup>1</sup>, HUANG Jinxian<sup>1</sup>, CHEN Chaohui<sup>1</sup>, LIU Liling<sup>2</sup>, CHENG Junping<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20260307&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[First successful restoration of ovarian endocrine function after childhood ovarian tissue cryopreservation and subsequent transplantation in China: a case report and literature review]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20260308&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］　Objective</b>　To explore the feasibility and effectiveness of ovarian tissue cryopreservation(OTC) and autologous transplantation in pre-adolescent female children for restoring ovarian endocrine function and inducing pubertal development. <b>Methods</b>　A retrospective analysis was conducted on a case of hemophagocytic syndrome. The patient underwent unilateral ovarian tissue cryopreservation at the age of 7 years before hematopoietic stem cell transplantation. After the transplantation, she developed ovarian failure and failed to initiate puberty. At the age of 12 years, autologous transplantation of the cryopreserved ovarian tissues was performed on her. Her sex hormone levels, uterine development and changes in signs of pubertal development were observed during the postoperative follow-up. <b>Results</b>　Four months after ovarian tissue transplantation, the patient′s follicle-stimulating hormone levels significantly decreased and uterine volume significantly increased, indicating the recovery of ovarian endocrine function. Eight months after the transplantation, the patient experienced menarche, and her breasts and vulva developed. Ultrasound examination showed multiple ovarian follicles in the graft, and her bone mineral density and height growth after the transplantation were significantly improved compared with those before the transplantation, indicating that the patient′s pubertal development was successfully induced. <b>Conclusion</b>　OTC before puberty and long-term preservation followed by autologous transplantation can still effectively restore the ovarian endocrine function of the transplanted child and induce her pubertal development, which provides an important strategy of fertility and endocrine function protection for the child patients who need to receive treatments leading to gonadal toxicity.]]></description>
<pubDate>2026/3/31 9:16:41</pubDate>
<category><![CDATA[Special Topic on Female Fertility Preservation]]></category>
<author><![CDATA[GU Muqing<sup>1</sup>, RUAN Xiangyan<sup>1</sup>, DU Juan<sup>1</sup>, JIN Fengyu<sup>1</sup>, CHENG Jiaojiao<sup>1</sup>, LI Yanglu<sup>1</sup>, LI Yanqiu<sup>1</sup>, WANG Zecheng<sup>1</sup>, ZHANG Mingzhen<sup>1</sup>, Matthias Korell<sup>2</sup>, Alfred O. Mueck<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GU Muqing<sup>1</sup>, RUAN Xiangyan<sup>1</sup>, DU Juan<sup>1</sup>, JIN Fengyu<sup>1</sup>, CHENG Jiaojiao<sup>1</sup>, LI Yanglu<sup>1</sup>, LI Yanqiu<sup>1</sup>, WANG Zecheng<sup>1</sup>, ZHANG Mingzhen<sup>1</sup>, Matthias Korell<sup>2</sup>, Alfred O. Mueck<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20260308&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>